Cabometyx (cabozantinib)

pCPA File Number: 22062

Negotiation Status:

Concluded with an LOI

Indication(s):

For the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory (RAI-R) or ineligible

Sponsor/Manufacturer:

Ipsen Biopharmaceuticals

CADTH Project Number:

PC0287

pCPA Engagement Letter Issued:

2023-04-25

Negotiation Process Concluded:

2023-09-14